Use of PKC inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection

摘要

A method for treating CMV infection and disease conditions associated therewith is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-ÄN,N'-1,1'-((2''-ethoxy)-3'''(O)-4'''-(N,N-dimethylamino)-buta ne)-bis-(3,3'-indoly1)Ü-1(H)-pyrrole-2,5-dione hydrochioride salt.